Nyrada, Inc. Shs Chess Depository Interests Repr 1 Shs
AASX:NYR0.47
AUD
0.00
(0.00%)
ISIN
AU0000070195
Return %
Stock
S&P 500
1Y
44.62
14.20
3Y
1,780.00
81.12
5Y
100.00
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- James Bonnar
- Full Time Employees
- 4,000
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Salesforce Tower, Sydney Place Sydney NSW Australia 2000
- IPO Date
- Jan 14, 2020
- Website
- nyrada.com
- Similar Companies
- Business
- Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company incorporated in Delaware, USA, in 2017 and headquartered at Sydney Place, Level 22/23, Salesforce Tower, 180 George Street, Sydney, NSW 2000, Australia, develops novel small-molecule drugs targeting Transient Receptor Potential Canonical (TRPC) ion channel inhibitors, primarily TRPC3/6/7, to treat cardiovascular, neurological, and inflammatory diseases with substantial unmet needs; its lead candidate, Xolatryp (formerly NYR-BI03), a first-in-class neuroprotectant and cardioprotectant based on the benzopyran scaffold, advances through four drug development programs focused on neuroprotection for stroke and traumatic brain injury, cardioprotection for acute myocardial infarction and ischemia-reperfusion injury, cholesterol-lowering, and chronic inflammatory conditions, targeting markets including civilian and military trauma patients via collaborations such as with the Walter Reed Army Institute of Research. The company lists CHESS Depositary Interests (CDIs) on the ASX and operates principally in Australia with global patent filings in Europe and North America. In 2025, Nyrada completed its first-in-human Phase I clinical trial of Xolatryp in healthy volunteers, dosing six cohorts without dose-limiting toxicities to assess safety, tolerability, and pharmacokinetics ahead of a planned Phase IIa trial in acute myocardial infarction; preclinical studies confirmed Xolatryp's 86% cardioprotective effect in myocardial ischemia-reperfusion, 42% cardiac injury reduction with three-hour infusion, and significant neuroprotection in penetrating traumatic brain injury models via MRI-validated lesion volume reduction; the company raised AU$3.45 million in October 2024 via placement and securities purchase plan, received AU$1.24 million R&D tax incentive in December 2024, strengthened its balance sheet with an AU$8.25 million placement in August 2025, filed composition-of-matter patents and a provisional patent for Xolatryp's structure, and rebranded NYR-BI03 to align with expanded cardioprotection and neuroprotection indications.
Company News
Marcus Frampton Acquires 600,000 Shares of Nyrada (ASX:NYR) Stock
Ruediger Weseloh Purchases 600,000 Shares of Nyrada (ASX:NYR) Stock
Christopher Cox Buys 600,000 Shares of Nyrada (ASX:NYR) Stock
John Moore Buys 1,200,000 Shares of Nyrada (ASX:NYR) Stock